Top Markets
Over time, the total annual drug spending is expected to grow due to biological and generic drugs and the contribution of emerging countries. According to IMS Health, in 2016 mature markets will account for 57% of the total (-10% compared to 2011) while 30% emerging markets will overtake the Top 5 Europe Countries (13% in 2016). In 2013, the global pharmaceutical expenditure will exceed a trillion USD to get to be close to 1.2 trillion in 2016. That same year, according to IMS Health spending in China will reach 161 billion, in Brazil will be 47 billion USD and in India 29 billion USD. In absolute terms, the annual total expenditure will increase from 30 billion USD in 2012 to 70 billion in 2016 and will be driven by an increase in per capita expenditure in mature markets (609 USD per capita/ ear) and in volume in emerging markets where the annual per capita expenditure will be 91 USD (121 USD for every Chinese and per 33USD each Indian).
Markets top 10 (2011-2016) – Source IMS Health
Rank | 2011 | 2016 |
1 | United States | United States |
2 | Japan | China |
3 | China | Japan |
4 | Germany | Brazil |
5 | France | Germany |
6 | Brazil | France |
7 | Italy | Italy |
8 | Spain | India |
9 | Canada | Russia |
10 | UK | Canada |
Sources
- IMS Institute for Healthcare Informatics- The Global Use Of Medicines Outlook: Through 2016 – July 2012;
- IMS Webinair: Changing Face of the Top 10 Pharmaceutical Companies, 5th March 2013
- PwC Health Research Institute – New chemistry: getting the biopharmaceutical talent formula right February 2013;http://www.pwc.com/us/en/health-industries/health-research-institute/publications/human-capital-pharma.jhtml
- KPMG LLP- 2012 Pharmaceutical & Life Science Industry Outlook Survey;
- http://www.genengnews.com